Latest research: Reflux and heartburn

Omeprazole and PPIs: short-term help, long-term risks for your gut

Omeprazole and other proton pump inhibitors (PPIs) are effective medicines for reflux, ulcers and H. pylori treatment, and for many people they are meant as a short course. With longer use, the evidence of downsides for the gut is growing. Regulators warn about low magnesium and fractures, and large studies link years of use to changes in gut bacteria, more gut infections, bacterial overgrowth and lower B12 and iron. Many of these are strong links rather than proven causes, so don't stop on your own: ask your GP or pharmacist for a review.

By The Gut Report editorial team. Updated . 11 minute read.

The short answer

  • In the short term, PPIs such as omeprazole are effective medicines. They ease reflux, help heal an inflamed food pipe and ulcers, and are part of H. pylori treatment.
  • NICE suggests a full-dose PPI for 4 or 8 weeks for reflux disease, then the lowest dose that controls symptoms, and a yearly review for anyone on long-term treatment.
  • The UK regulator, the MHRA, warns that long-term use can cause low magnesium and is linked to a modest rise in fractures. The US regulator warned about C. difficile gut infections.
  • Large studies link PPI use with less varied gut bacteria and more mouth-type bacteria, such as Streptococcus, in the gut. PPI users also have higher odds of Salmonella, Campylobacter and C. difficile infections.
  • Stomach acid helps digest protein and absorb B12 and iron. Two large studies linked 2 or more years of PPIs with higher odds of low B12 and iron deficiency.
  • Stopping suddenly can cause rebound acid, so plan any change with your GP or pharmacist, and keep taking your medicine until you have spoken to them.

How does omeprazole work?

Omeprazole is a proton pump inhibitor (PPI), like lansoprazole, esomeprazole and pantoprazole.

Your stomach lining has cells that make acid, using tiny pumps called proton pumps. PPIs block these pumps, so the stomach makes much less acid. That helps when acid is causing damage, but it also turns down the useful jobs acid does, for as long as you take the medicine.

What PPIs do well in the short term

In the short term, PPIs are effective and often needed. The NHS lists omeprazole for:

  • heartburn and gastro-oesophageal reflux disease (GORD), where acid repeatedly comes back up into the food pipe
  • treating and preventing stomach ulcers
  • clearing the stomach infection Helicobacter pylori (H. pylori), alongside antibiotics

NICE also uses PPIs to heal severe oesophagitis (an inflamed food pipe), and to protect the stomach in some people who need to keep taking anti-inflammatory painkillers.

For many people, though, a PPI is meant as a short course. NICE suggests a full-dose PPI for 4 or 8 weeks for GORD. If symptoms come back, it suggests the lowest dose that controls them, and talking about taking it only when needed. The NHS says not to take omeprazole you bought without a prescription for longer than 2 weeks without advice.

Some people do need long-term treatment. NICE advises it for severe oesophagitis and after a narrowed food pipe has been stretched. A 2022 American Gastroenterological Association (AGA) update adds Barrett's oesophagus and a high risk of stomach bleeding.

Why stomach acid matters for your gut

Stomach acid does several jobs that matter for digestion and gut health.

  • Digesting protein. The stomach releases an enzyme in an inactive form. A 2023 review explains that acid switches it into pepsin, which starts breaking protein down.
  • Absorbing nutrients. Acid helps release vitamin B12 from food and helps the body take up iron and some other minerals.
  • Defending against germs. A 2005 review describes killing swallowed microbes as acid's main job. This acid barrier stops most harmful germs reaching the intestine.

So lowering acid for months or years could have knock-on effects further down the gut, and research increasingly suggests it does.

What happens to your gut with long-term PPI use?

The NHS says serious side effects are more likely if you take omeprazole for a year or more. Here are the main concerns, starting with the firmest evidence.

Regulator warnings: magnesium, bones and skin

These are official warnings from the MHRA, the UK medicines regulator.

  • Low magnesium. Severe low magnesium has been reported, though infrequently. Most cases appeared after about a year of treatment, and some after 3 months. Signs can include tiredness, muscle spasms, dizziness, confusion, fits and an irregular heartbeat. The MHRA advises doctors to consider checking magnesium before and during long-term treatment, especially in people taking digoxin or diuretics (water tablets).
  • Fractures. The MHRA says studies suggest a modest rise in the risk of hip, wrist and spine fractures, by about 10–40%. The rise was seen mainly in older people, and with high doses taken for over a year. It advises that people at risk of weak bones get enough vitamin D and calcium.
  • A skin reaction. In 2015 the MHRA warned of a very small risk of subacute cutaneous lupus, a red, scaly rash on sun-exposed skin, sometimes with joint pain. It usually clears after the PPI is stopped.

Changes to gut bacteria, including Streptococcus

Two large studies published in the journal Gut in 2016 found clear differences in the gut bacteria of PPI users.

  • Imhann and colleagues studied 1,815 people, 211 of them taking PPIs. PPI users had less varied gut bacteria, with changes in about 20% of the bacterial groups measured. Mouth bacteria were more common in their stool, as were Streptococcus, Enterococcus, Staphylococcus and E. coli. The authors said these were changes towards a less healthy gut microbiome. Across the population, PPIs were linked to bigger differences than antibiotics.
  • Jackson and colleagues studied 1,827 healthy twins. PPI users had fewer of the usual gut bacteria and more mouth and throat bacteria, especially the Streptococcaceae family. The same pattern showed up in 70 pairs of identical twins where only one twin took a PPI. The researchers think less acid lets bacteria from the mouth survive the journey down the gut. They said their findings "should caution over-use of PPIs".

A 2022 study also found more Streptococcaceae in the stool of PPI users. These are strong, repeated links, but what they mean for long-term health is still being worked out.

Clinicians are paying attention to this. UK upper GI surgeon Nick Boyle, writing for the RefluxUK clinic network, describes stomach acid as a barrier against harmful bacteria that PPIs may weaken, and says the effect on the gut microbiome should be part of any discussion about long-term use.

More gut infections, including C. difficile

With less acid, more swallowed germs survive. Research consistently links PPIs with more gut infections.

  • Salmonella and Campylobacter. A 2007 review in the American Journal of Gastroenterology pooled 6 studies of 11,280 people. People with these and similar gut infections had about 3 times the odds of taking a PPI. A 2011 review found similar or larger risks, though from only a few studies.
  • C. difficile. This bacterium can cause severe diarrhoea, often after antibiotics. A 2018 meta-analysis of 50 observational studies found PPI users had about 26% higher odds of getting it. The authors said further trials were unlikely to overturn this result. In 2012 the US regulator, the FDA, warned that PPIs may raise the risk, and advised people on PPIs with diarrhoea that doesn't improve to seek medical advice.
  • The best trial agrees. A 2019 trial gave 17,598 people pantoprazole or a dummy pill for about 3 years. Gut infections were more common with the PPI (1.4% compared with 1.0%). C. difficile was about twice as common, though there were too few cases to be sure. As a randomised trial, it supports the idea that PPIs themselves raise infection risk.

Pneumonia and Streptococcus pneumoniae

PPIs have also been linked with chest infections. A 2015 meta-analysis of 26 studies found PPI users had about 1.5 times the odds of pneumonia caught in the community. The risk was highest in the first month of treatment, so this isn't only about long-term use.

A 2012 study of 463 people with pneumonia found that PPI users were about twice as likely to be infected with Streptococcus pneumoniae, a common cause of pneumonia. Bacteria from the mouth and throat were also more common. The large 2019 trial didn't find a clear difference in pneumonia, so this link is less certain than the gut infection link.

SIBO: bacteria in the small intestine

SIBO, or small intestinal bacterial overgrowth, means too many bacteria in the small intestine. It can cause bloating, wind and diarrhoea.

  • Lo and Chan (2013) pooled 11 studies of 3,134 people. PPI users had about twice the odds of SIBO. The link was strongest with the most accurate test, a fluid sample from the small intestine.
  • Su and colleagues (2018) pooled 19 studies of 7,055 people and found odds about 1.7 times higher.
  • Lombardo and colleagues (2010) used breath tests in 450 people. SIBO was found in 50% of 200 long-term PPI users, compared with 6% of 50 healthy people, and became more common after a year of treatment.

Not every study agrees. The 2022 study, which sampled the small intestine directly, found similar SIBO rates in PPI users and non-users. We cover this in more detail in SIBO: symptoms, causes and the PPI link.

Poorer digestion of protein

Because acid switches on pepsin, less acid may mean less protein is broken down in the stomach. A small 1998 study tested this. In 16 healthy people, omeprazole significantly reduced how well protein was absorbed. People who had taken omeprazole for over a month also had more by-products of protein fermentation in their urine. That suggests more undigested protein was reaching bacteria in the large bowel. The authors concluded that acid suppression may promote protein malabsorption. It was small, so it needs confirming.

Lower B12, iron and other nutrients

Two large studies by the same research team looked at this.

  • Vitamin B12. A 2013 study in JAMA compared about 26,000 people with low B12 against 184,000 without. Two or more years' supply of a PPI was linked to about 65% higher odds of low B12, and higher doses to higher odds. The NHS lists PPIs among medicines that can lower B12.
  • Iron. A 2017 study compared 77,046 people with new iron deficiency against 389,314 without. Two or more years of PPIs was linked to about 2.5 times the odds. The link was strongest with higher doses for 10 years or more, and it weakened after people stopped.

A 2013 review also linked PPIs with lower vitamin C, calcium and magnesium. It judged the risk low for most people, but more important for older or poorly nourished people.

Can low stomach acid make food ferment?

Some clinicians argue that long-term low acid lets more bacteria survive and more food pass through partly digested. That food may then ferment, making gas, bloating and wind. Some suggest this pressure could push stomach contents upwards and add to reflux.

Parts of this idea fit the evidence above:

  • PPIs are linked to more mouth-type bacteria in the gut, and in several studies to SIBO.
  • The 1998 study found signs of more protein fermentation in long-term omeprazole users.
  • A 2011 study followed 42 people with reflux on esomeprazole twice a day for 6 months. After 8 weeks, 43% reported bloating and 17% wind. After 6 months, 26% had a positive SIBO breath test. There was no comparison group, so other causes can't be ruled out. The authors still encouraged stepping down or using a PPI only when needed.
  • A small 2003 study of 9 people with reflux found that fermenting a type of fibre in the bowel increased valve relaxations and reflux episodes. It didn't involve PPIs, but shows that fermentation can affect reflux.

What's missing is a trial that directly tests whether PPI-related fermentation causes reflux. Studies of people with atrophic gastritis, who naturally make little acid, have found less reflux rather than more. A 2022 study of 12,533 Swedish twins found about half the odds of frequent reflux in people with blood markers of atrophic gastritis. So this is a reasonable idea with some supporting evidence, but it isn't proven. We look at it further in Low stomach acid.

Some observational studies have raised wider concerns:

  • Dementia. A 2016 German study of 73,679 people aged 75 and over found regular PPI users had a 44% higher risk of a dementia diagnosis.
  • Kidneys. A 2016 study of 10,482 adults linked PPI use with a higher risk of chronic kidney disease. PPIs are also linked to a rarer kidney inflammation called acute interstitial nephritis.

The 2019 trial didn't find a clear difference in dementia or kidney disease over about 3 years. These remain debated associations, not proven effects.

What guidelines now say about long-term use

Guidelines increasingly stress that long-term PPIs should be checked, not just repeated.

  • NICE says anyone on long-term treatment should be offered a yearly review. It encourages stepping down or stopping, unless there is a condition or another medicine that means you need to keep going.
  • The AGA's 2022 update says everyone on a PPI should have the reason written down and regularly reviewed, led by their GP. People without a clear reason for long-term use should be considered for a trial of coming off. Most people on twice-daily doses should be considered for once daily.

The AGA judges PPIs generally safe, and says the decision to stop should rest on whether you still need one. The downsides above are a good reason to make sure that check actually happens.

Stopping safely: rebound acid

Please don't stop a PPI on your own. When you stop suddenly, the stomach can briefly make more acid than before. This is called rebound acid. In a 2009 trial, 120 healthy volunteers took a PPI or a dummy pill for 8 weeks. In the 4 weeks after the PPI stopped, 44% of the PPI group had acid symptoms, compared with 15% of the dummy-pill group.

It can feel as though your reflux is back. That's why changes are best planned with your GP or pharmacist. Options include going from twice to once a day, lowering the dose gradually or taking it only when needed. Read Coming off omeprazole for a full guide.

Everyday habits that can help

The NHS suggests these changes to ease reflux:

  • eating smaller, more frequent meals
  • not eating within 3 to 4 hours of going to bed
  • raising the head of your bed by 10 to 20 cm, rather than using extra pillows
  • losing weight if you're overweight, and finding ways to relax
  • avoiding your own trigger foods and drinks, cutting down on alcohol and not smoking

View our top recommended gut support supplements to go alongside the lifestyle changes in this article.

When should you see a GP?

See a GP if:

  • you have taken a PPI for a long time and haven't had a review in the last year
  • heartburn happens most days, or pharmacy medicines aren't helping
  • food gets stuck when you swallow, you are being sick often, or you're losing weight without trying
  • you feel very tired, dizzy or weak, or have muscle twitches or cramps while taking a PPI
  • you have diarrhoea that doesn't settle while taking a PPI

The NHS notes that omeprazole can hide the symptoms of some serious conditions, so mention any new or changing symptoms. If symptoms get worse, contact your GP or call 111.

If you're worried about your medicine, keep taking it until you have spoken to your GP or pharmacist. A review is a normal, routine check.

This is general information, not medical advice. See a GP if your symptoms are new, severe or getting worse, or if you notice blood in your poo or lose weight without trying. Don’t stop or change a prescribed medicine without speaking to your GP or pharmacist.

Questions people ask

Is it safe to take omeprazole long term?
For some people, such as those with severe oesophagitis or Barrett's oesophagus, long-term use is the right choice. But the NHS says serious side effects are more likely after a year or more, and regulators warn about low magnesium and fractures. NICE advises a yearly review for anyone taking it long term.
Can omeprazole cause infections?
Research links PPIs with more gut infections. Meta-analyses found higher odds of C. difficile, Salmonella and Campylobacter in PPI users, and a large 3-year trial also found more gut infections with a PPI than with a dummy pill. Studies also link PPIs with pneumonia, though that link is less certain.
Does omeprazole affect gut bacteria?
Yes, according to large studies. Two 2016 studies of more than 1,800 people each found PPI users had less varied gut bacteria and more bacteria normally found in the mouth, such as Streptococcus. Whether this harms health in the long run is still being studied.
Can omeprazole cause poor digestion or bloating?
It may for some people. Acid switches on pepsin, the stomach's protein-digesting enzyme, and a small study found omeprazole reduced protein absorption. In another small study, bloating and wind became common during 6 months of a PPI, and some people developed bacterial overgrowth.
Does omeprazole stop you absorbing vitamins?
It can lower how well you absorb some nutrients. Large studies linked 2 or more years of PPIs with higher odds of low vitamin B12 and iron deficiency, and the MHRA warns about low magnesium. Your GP can check your levels with a blood test.
What happens if you stop taking omeprazole suddenly?
Some people get a short-term rebound in heartburn or indigestion, because the stomach briefly makes more acid. In one trial, this happened even in healthy volunteers after 8 weeks of a PPI. A GP or pharmacist can help you plan a gradual step-down.

Sources

  1. Effects of PPIs on the gut microbiome. RefluxUK (Mr Nick Boyle, upper GI surgeon), 2023
  2. Omeprazole. NHS
  3. Common questions about omeprazole. NHS
  4. Heartburn and acid reflux. NHS
  5. Vitamin B12 or folate deficiency anaemia: causes. NHS
  6. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184). NICE, 2014
  7. Proton pump inhibitors in long-term use: reports of hypomagnesaemia. MHRA Drug Safety Update, 2012
  8. Proton pump inhibitors in long-term use: increased risk of fracture. MHRA Drug Safety Update, 2012
  9. Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus. MHRA Drug Safety Update, 2015
  10. Clostridium difficile diarrhoea associated with the use of proton pump inhibitors: FDA safety communication. AIFA (Italian Medicines Agency), 2012
  11. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology (Targownik LE et al.), 2022
  12. Proton pump inhibitors affect the gut microbiome. Gut (Imhann F et al.), 2016
  13. Proton pump inhibitors alter the composition of the gut microbiota. Gut (Jackson MA et al.), 2016
  14. Effects of proton pump inhibitors on the small bowel and stool microbiomes. Digestive Diseases and Sciences (Weitsman S et al.), 2022
  15. Systematic review of the risk of enteric infection in patients taking acid suppression. American Journal of Gastroenterology (Leonard J et al.), 2007
  16. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary Pharmacology & Therapeutics (Bavishi C, DuPont HL), 2011
  17. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. Journal of Hospital Infection (Cao F et al.), 2018
  18. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology (Moayyedi P et al.), 2019
  19. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One (Lambert AA et al.), 2015
  20. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Alimentary Pharmacology & Therapeutics (de Jager CP et al.), 2012
  21. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clinical Gastroenterology and Hepatology (Lo WK, Chan WW), 2013
  22. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. Journal of Gastroenterology (Su T et al.), 2018
  23. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clinical Gastroenterology and Hepatology (Lombardo L et al.), 2010
  24. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. European Journal of Clinical Investigation (Compare D et al.), 2011
  25. Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy. Alimentary Pharmacology & Therapeutics (Evenepoel P et al.), 1998
  26. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology (Piche T et al.), 2003
  27. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA (Lam JR et al.), 2013
  28. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology (Lam JR et al.), 2017
  29. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Therapeutic Advances in Drug Safety (Heidelbaugh JJ), 2013
  30. Physiology, Pepsin. StatPearls (Heda R et al.), 2023
  31. Gastric juice: a barrier against infectious diseases. Basic & Clinical Pharmacology & Toxicology (Martinsen TC et al.), 2005
  32. Atrophic gastritis is inversely associated with gastroesophageal reflux disease in a twin register based study. United European Gastroenterology Journal (Zhang J et al.), 2022
  33. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurology (Gomm W et al.), 2016
  34. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Internal Medicine (Lazarus B et al.), 2016
  35. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology (Reimer C et al.), 2009